. Atypical breakpoints in BCR may also be found. In the neutrophilic variant of chronic myeloid leukemia (CML), e19a2 transcripts result in a p230 BCR/ABL fusion protein. Sporadic cases with b2a3 or b3a3 can also be found. The rare e6a2 transcript, resulting in a fusion protein of 185 kDa, has been reported in only eight cases and it has been suggested that e6a2 may confer a worse prognosis. [1] [2] [3] [4] [5] [6] [7] [8] We described here a case of acute megakaryoblastic leukemia (AML) with the e6a2 transcript, successfully treated with dasatinib and reduced-conditioning allogeneic hematopoietic stem cell transplantation.
A 53-year-old woman was admitted in March 2005. She had a history of asthenia and abdominal pain over the previous few months. Her peripheral blood showed mild anemia and erythromyelemia. On referral, her performance status was 3, she had a fever of 391C, plus splenomegaly and pleural effusion. Her white blood count was 23 Â 10 9 /l with 5% polymorphonuclear cells, 21% lymphocytes, 3% monocytes, 39% blasts, 16% basophils, 7% micromegakaryocytes and 7% erythromyelemia. Her bone marrow aspirate was hypocellular, with 32% blast cell infiltration and a negative peroxidase test. Blast cells were CD13 þ , CD31 þ , CD41 þ and CD61 þ , suggesting megakaryoblastic AML. Bone marrow biopsy confirmed the diagnosis, with massive blastic infiltration and severe collagen fibrosis. Standard cytogenetic testing showed a 46, XX, t(9;22)(q34;q11), del(18)(p10) [15] karyotype. Molecular analysis showed no amplification product for primers detecting b2a2 and b3a2. Direct sequencing of the PCR product showed an e6a2 fusion transcript.
Treatment was initiated immediately, with 800 mg/day imatinib combined 2 days later with 12 mg/m 2 /day idarubicin and 100 mg/m 2 /day cytarabine (continuous infusion). On day 2, the patient had to be transferred to intensive care because of a severe sepsis with toxic shock, which led to pleuropneumopathy and convulsions. Chemotherapy was discontinued and she was treated with imatinib alone, decreased to 400 mg/day after March 28th due to severe generalized edema and cardiomegaly, with FEV decreased to 25%. At 10 days later, blast cell count increased again. Ineffectiveness and severe side effects prompted us to discontinue imatinib on April 5th, and start dasatinib 70 mg twice daily on April 11th. This led to a period of aplasia and she required 45 days to reach 0.5 Â 10 9 /l PMN, after which bone marrow aspirate and bone marrow biopsy showed blast clearance, but on a hypocellular marrow, with persistent collagen fibrosis. The pleural effusion persisted under dasatinib and required many evacuations. We hypothesized that it was secondary to the AML, and was maintained by dasatinib. Cytogenetic analysis after 2 months showed a complete response. In spite of blood and bone marrow blast clearance, hematological recovery was not complete, with persistent thrombopenia and anemia necessitating transfusion. The patient was scheduled for transplant.
Dasatinib was stopped, and the patient then received a reduced conditioning (fludarabine 30 mg/m 2 /day Â 3, TBI 2 Gy). On September 7th, 10 days after dasatinib was stopped, she received a genoidentical hematopoietic stem cell transplant. Hematological relapse was noted on day 97 after transplant (December 13th). On day 105, dasatinib was recommenced at the original dose and cyclosporine and mycophenolate mofetil were discontinued to decrease immunosuppression. A new complete cytogenetic and hematological response was obtained. The pleural effusion did not reappear. Chimerism analysis showed a persistent donor profile while on dasatinib. On day 127, the patient developed grade III GVHD that was controlled with corticosteroids. Corticosteroids were discontinued in September 2006.
In March 2007, after 15 months of dasatinib plus reduced immunosuppression, the patient is still showing hematological, cytogenetic and molecular complete responses, with chimerism analysis showing a complete donor profile. No side effects of dasatinib were observed.
The BCR/ABL e6a2 fusion has been reported only nine times, including the present report (Table 1) . Cases were heterogeneous. Colla et al. 4 have suggested that this transcript could be associated with aggressive disease, because its protein partially lacks the guanine exchange factor/dbl-like domain, and thus may not interact with small G proteins. Among the nine cases, three were diagnosed as AML or blast crisis of CML. Another five were diagnosed with chronic phase CML, but two died less than a year from diagnosis. Thus, the e6a2 transcript Letters to the Editor probably confers a higher capacity to transform into acute disease. However, these patients clearly benefited from use of tyrosine kinase inhibitors. Among the six patients treated with these drugs, five attained hematological and cytogenetic response. Our case is the first report of primary resistance to imatinib, followed by response to dasatinib. Dasatinib has demonstrated efficacy in myeloid blast crisis of CML, which responds poorly and transiently to imatinib. 9 In our case, imatinib failed, but dasatinib induced a partial response and was also effective against relapse after transplant. After relapse, dasatinib probably acted in synergy with the enhanced graftversus-leukemia effect to induce the complete molecular remission and to maintain it. Malignancies with e6a2 BCR/ABL may be aggressive on presentation, but with modern treatments they respond like malignancies with p210 BCR/ABL. Systematic recording of e6a2 cases, with long-term follow-up, are necessary to confirm these findings. Asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukemia (ALL). Its influence on the coagulation system has been extensively studied. 1 Asparaginase is an enzyme leading to serum depletion of asparagine and glutamine. Consequently, protein synthesis is depressed leading to coagulation protein deficiencies as a side effect of antileukemic treatment. The effect on antithrombotic proteins might induce an increased risk for thrombosis, while the effects on procoagulant proteins might increase the bleeding risk. Asparaginase is usually given in combination with other chemotherapeutic drugs among which especially corticosteroids may also influence the coagulation system. Corticosteroids may induce hypofibrinogenemia potentially leading to bleeding, but also increase the risk for thrombotic events by the induction of a hypofibrinolytic state in combination with an increase in procoagulant factors. 2 So, in general, it is difficult to analyze which coagulation disorders in children with ALL are due to asparaginase and which are due to concomitant use of other drugs such as corticosteroids. In this study, we analyzed the influence of both these drugs (Paronal and dexamethasone) in one group of children during two different parts of ALL therapy.
During induction, according to the DCOG (Dutch Childhood Oncology Group)-ALL-9 treatment schedule, 3 24 children with high-risk ALL were treated with among others dexamethasone from day 1 to day 29 followed by 15 days of tapering to zero and four doses of Paronal (6000 IU/m 2 ) on days 29, 33, 36 and 40. During the intensification phase of this protocol, the treatment included one weekly dose of Paronal (10 000 IU/m 2 ) during 9 weeks and 7 days of dexamethasone once every 3 weeks during the same 9 weeks (Figure 1 ).
Blood samples were collected immediately before each Paronal infusion to analyze procoagulant (fibrinogen, F II, F V, F VII, F IX, F X) and anticoagulant factors (antithrombin, protein C, protein S) and parameters of thrombin generation (F1 þ 2, thrombin-antithrombin (TAT) complex) and fibrinolysis (a2-antiplasmin, plasminogen, plasmin-a2 antiplasmin (PAP) complex, D-dimer).
After 4 weeks of dexamethasone on day 29, all procoagulant and anticoagulant factors demonstrated high levels, and a hypofibrinogenemia was observed (Figures 2 and 3) . The four doses of Paronal and tapering of the dose of dexamethasone (days 29-43) had the following effects on the procoagulant parameters:
after an initial further decrease, fibrinogen levels stabilized at low levels or increased slightly ( Figure 2a) ; F V levels stabilized at high levels ( Figure 2b) ; F II, IX and X normalized ( Figure 2c) ;
